Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Net Income towards Common Stockholders (2019 - 2025)

Revolution Medicines has reported Net Income towards Common Stockholders over the past 7 years, most recently at -$364.9 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$364.9 million for Q4 2025, down 87.54% from a year ago — trailing twelve months through Dec 2025 was -$1.1 billion (down 88.52% YoY), and the annual figure for FY2025 was -$1.1 billion, down 88.52%.
  • Net Income towards Common Stockholders for Q4 2025 was -$364.9 million at Revolution Medicines, down from -$305.2 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for RVMD hit a ceiling of -$37.2 million in Q1 2021 and a floor of -$364.9 million in Q4 2025.
  • Median Net Income towards Common Stockholders over the past 5 years was -$103.4 million (2023), compared with a mean of -$130.2 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: fell 8.07% in 2022 and later plummeted 183.76% in 2023.
  • Revolution Medicines' Net Income towards Common Stockholders stood at -$52.7 million in 2021, then decreased by 8.07% to -$56.9 million in 2022, then plummeted by 183.76% to -$161.5 million in 2023, then dropped by 20.45% to -$194.6 million in 2024, then crashed by 87.54% to -$364.9 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$364.9 million (Q4 2025), -$305.2 million (Q3 2025), and -$247.8 million (Q2 2025) per Business Quant data.